706 related articles for article (PubMed ID: 28918943)
1. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.
Farrand AQ; Helke KL; Gregory RA; Gooz M; Hinson VK; Boger HA
Brain Stimul; 2017; 10(6):1045-1054. PubMed ID: 28918943
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson's disease.
Farrand AQ; Verner RS; McGuire RM; Helke KL; Hinson VK; Boger HA
Brain Stimul; 2020; 13(5):1323-1332. PubMed ID: 32629028
[TBL] [Abstract][Full Text] [Related]
3. Effects of vagus nerve stimulation are mediated in part by TrkB in a parkinson's disease model.
Farrand AQ; Helke KL; Aponte-Cofresí L; Gooz MB; Gregory RA; Hinson VK; Boger HA
Behav Brain Res; 2019 Nov; 373():112080. PubMed ID: 31301412
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Srinivasan J; Schmidt WJ
Eur J Neurosci; 2003 Jun; 17(12):2586-92. PubMed ID: 12823465
[TBL] [Abstract][Full Text] [Related]
5. Differential interactive effects of gliotoxin and MPTP in the substantia nigra and the locus coeruleus in BALB/c mice.
Chang FW; Wang SD; Lu KT; Lee EH
Brain Res Bull; 1993; 31(3-4):253-66. PubMed ID: 7683960
[TBL] [Abstract][Full Text] [Related]
6. Lesioning noradrenergic neurons of the locus coeruleus in C57Bl/6 mice with unilateral 6-hydroxydopamine injection, to assess molecular, electrophysiological and biochemical changes in noradrenergic signaling.
Szot P; Knight L; Franklin A; Sikkema C; Foster S; Wilkinson CW; White SS; Raskind MA
Neuroscience; 2012 Aug; 216():143-57. PubMed ID: 22542679
[TBL] [Abstract][Full Text] [Related]
7. Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss.
Iravani MM; Sadeghian M; Rose S; Jenner P
J Neural Transm (Vienna); 2014 Dec; 121(12):1493-505. PubMed ID: 24781752
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
9. The antidepressant-like effect of vagus nerve stimulation is mediated through the locus coeruleus.
Grimonprez A; Raedt R; Portelli J; Dauwe I; Larsen LE; Bouckaert C; Delbeke J; Carrette E; Meurs A; De Herdt V; Boon P; Vonck K
J Psychiatr Res; 2015 Sep; 68():1-7. PubMed ID: 26228393
[TBL] [Abstract][Full Text] [Related]
10. Auricular Vagus Nerve Stimulation Exerts Antiinflammatory Effects and Immune Regulatory Function in a 6-OHDA Model of Parkinson's Disease.
Jiang Y; Cao Z; Ma H; Wang G; Wang X; Wang Z; Yang Y; Zhao H; Liu G; Li L; Feng T
Neurochem Res; 2018 Nov; 43(11):2155-2164. PubMed ID: 30311182
[TBL] [Abstract][Full Text] [Related]
11. Restoration of Noradrenergic Function in Parkinson's Disease Model Mice.
Cui K; Yang F; Tufan T; Raza MU; Zhan Y; Fan Y; Zeng F; Brown RW; Price JB; Jones TC; Miller GW; Zhu MY
ASN Neuro; 2021; 13():17590914211009730. PubMed ID: 33940943
[TBL] [Abstract][Full Text] [Related]
12. Targeting the norepinephrinergic system in Parkinson's disease and related disorders: The locus coeruleus story.
Vermeiren Y; De Deyn PP
Neurochem Int; 2017 Jan; 102():22-32. PubMed ID: 27899296
[TBL] [Abstract][Full Text] [Related]
13. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra.
Bing G; Zhang Y; Watanabe Y; McEwen BS; Stone EA
Brain Res; 1994 Dec; 668(1-2):261-5. PubMed ID: 7704612
[TBL] [Abstract][Full Text] [Related]
14. IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases.
Ayadi AE; Zigmond MJ; Smith AD
Exp Brain Res; 2016 Jul; 234(7):1863-1873. PubMed ID: 26894890
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/c mice.
Hu SC; Chang FW; Sung YJ; Hsu WM; Lee EH
J Pharmacol Exp Ther; 1991 Dec; 259(3):1379-87. PubMed ID: 1684822
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism.
Kreiner G; Rafa-Zabłocka K; Barut J; Chmielarz P; Kot M; Bagińska M; Parlato R; Daniel WA; Nalepa I
Sci Rep; 2019 Mar; 9(1):5262. PubMed ID: 30918302
[TBL] [Abstract][Full Text] [Related]
17. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
18. Progressive loss of nigrostriatal dopaminergic neurons induced by inflammatory responses to fipronil.
Park JH; Park YS; Koh HC
Toxicol Lett; 2016 Sep; 258():36-45. PubMed ID: 27313094
[TBL] [Abstract][Full Text] [Related]
19. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
20. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
